eye disease

Ocuphire to transform into gene therapy biotech via Opus buyout

Ocuphire is acquiring gene therapy developer Opus in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity.

James Waldron Oct 23, 2024 5:31am

Two thirteen-lined ground squirrels fight over a piece of food

Hibernating squirrels hold protein that clears cataracts: study

Sep 20, 2024 11:58am

Beacon attracts $170M series B to fund eye disease gene therapy

Jul 3, 2024 5:00am

Innovent's anti-VEGF drug matches Eylea in eye disease trial

Mar 19, 2024 10:36am

gift give present christmas package holidays

MeiraGTx gifts last of gene therapy rights to J&J for $415M

Dec 21, 2023 10:14am

ProQR, Théa ink new pact for eye assets after old one collapsed

Dec 8, 2023 11:01am